Sequoia Financial Advisors LLC Purchases 4,485 Shares of AbbVie Inc. $ABBV

Sequoia Financial Advisors LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 5.6% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 84,494 shares of the company’s stock after buying an additional 4,485 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in AbbVie were worth $19,564,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Hartline Investment Corp raised its stake in AbbVie by 25.1% in the 3rd quarter. Hartline Investment Corp now owns 12,288 shares of the company’s stock worth $2,845,000 after purchasing an additional 2,462 shares in the last quarter. Financial Management Network Inc. increased its holdings in shares of AbbVie by 50.2% during the third quarter. Financial Management Network Inc. now owns 3,627 shares of the company’s stock worth $835,000 after purchasing an additional 1,212 shares during the period. Occidental Asset Management LLC raised its position in shares of AbbVie by 18.4% in the third quarter. Occidental Asset Management LLC now owns 9,544 shares of the company’s stock valued at $2,210,000 after buying an additional 1,485 shares in the last quarter. Howland Capital Management LLC raised its position in shares of AbbVie by 1.0% in the third quarter. Howland Capital Management LLC now owns 28,777 shares of the company’s stock valued at $6,663,000 after buying an additional 286 shares in the last quarter. Finally, Alesco Advisors LLC boosted its stake in shares of AbbVie by 35.9% in the third quarter. Alesco Advisors LLC now owns 3,620 shares of the company’s stock valued at $838,000 after buying an additional 956 shares during the period. 70.23% of the stock is owned by institutional investors.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

AbbVie Trading Down 1.1%

Shares of NYSE ABBV opened at $214.38 on Friday. The company has a market cap of $378.89 billion, a price-to-earnings ratio of 162.41, a PEG ratio of 0.88 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a 50-day moving average price of $226.80 and a two-hundred day moving average price of $216.47.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm posted $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is currently 524.24%.

Analysts Set New Price Targets

A number of equities analysts have commented on ABBV shares. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. Cantor Fitzgerald set a $250.00 price target on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Evercore ISI increased their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Finally, Morgan Stanley boosted their target price on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $247.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.